{"filings":[{"id":555557,"accession_number":"0001356576-26-000025","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2026-05-20T20:37:01+00:00","items":["2.03","9.01"],"status":"ready","headline":"Supernus to pay $33.4M CVR milestone payment after Milestone 1 achieved March 18","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Milestone 1 under July 2025 CVR Agreement achieved on March 18, 2026; triggers $0.50 per CVR payment.","Aggregate milestone payment ~$33.4 million, payable in cash within 20 business days of May 17, 2026 Notice Date.","Company will deposit funds with Rights Agent Equiniti Trust Company for distribution to CVR holders.","CVRs were issued as part of prior business combination; this payment reduces future contingent liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92387,"accession_number":"0001356576-26-000020","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus Q1 revenue $207.7M (+39% YoY); growth products up 56%; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $207.7M, up 39% YoY; combined growth product revenues $149.1M (+56%).","Qelbree net sales $77.9M (+20%), GOCOVRI $35.2M (+15%), ONAPGO $8.4M, ZURZUVAE collab revenue $27.6M (U.S. sales doubled per Biogen).","ONAPGO second supplier FDA submission expected Q3 2026; potential approval mid-2027.","Pipeline: SPN-817 (epilepsy) Phase 2b enrolling; SPN-820 (MDD) Phase 2b ongoing; SPN-443 (ADHD) Phase 1 expected H2 2026.","Company reiterates full year 2026 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":207705000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92386,"accession_number":"0001356576-26-000015","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus to report Q1 2026 results on May 5, 2026 after market close","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Results announced after close May 5, 2026; conference call at 4:30 PM ET.","Call hosted by CEO Jack Khattar and CFO Tim Dec; Q&A session to follow.","Live webcast accessible via supernus.com/investors; replay available for 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92385,"accession_number":"0001104659-26-040497","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Supernus acquires NV-5138/SPN-820 assets from Navitor; up to $350M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Supernus buys all IP, inventory, and regulatory materials for CNS compound NV-5138 (SPN-820).","Consideration: complete a Phase 2b study plus milestone payments up to $350M tied to development, regulatory, and commercial goals.","No upfront cash; Supernus may stop pursuing milestones if Phase 2b study fails in its sole discretion.","Agreement includes five-year post-closing non-compete and non-solicitation covenants for Navitor parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103215,"accession_number":"0001356576-26-000007","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Supernus raises CEO salary to $1.067M, awards $847K bonus and equity grants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO salary increased to $1,067,100 from $1,036,000; 2025 bonus $846,930.","CEO granted options for 341,610 shares and 204,966 PSUs at $50.20 strike.","CFO salary raised to $525,100 from $504,900; 2025 bonus $233,894.","CFO gets 17,500 options, 3,000 RSUs, and 3,500 PSUs.","Three other execs (Bhatt, Rubin, Mottola) also received salary increases and equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103214,"accession_number":"0001356576-26-000004","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus Q4 revenue $211.6M (+21% YoY), FY revenue $719M (+9%); FY26 guidance $840-870M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 total revenue $211.6M (+21% YoY); full year $719.0M (+9% YoY).","Growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) combined revenue $161.3M in Q4 (+45% YoY).","ONAPGO net sales $8.9M since launch; new patient initiation resumed Q1 2026; second supplier expected 2027.","Cash and marketable securities $308.7M at Dec 31, 2025.","FY 2026 guidance: revenue $840-870M, operating earnings $0-30M, adjusted operating earnings $140-170M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":718952000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103213,"accession_number":"0001356576-26-000002","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus schedules Q4 2025 earnings release for Feb 24, 2026 after market close","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 and full year 2025 results to be reported after market close on February 24, 2026.","Conference call and webcast at 4:30 p.m. ET on February 24, 2026, hosted by CEO Jack Khattar and CFO Tim Dec.","No preliminary financial results or guidance provided in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":718952000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103212,"accession_number":"0001628280-26-003907","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Supernus amends 2018 merger agreement milestone terms with Reich Consulting","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["First Amendment to Merger Agreement dated September 12, 2018, entered on January 22, 2026.","Amendment adjusts timing and payment terms for certain milestones under the original deal.","Exhibit 10.1 filed with limited redactions for non-material, competitively harmful details.","No financial figures or revised milestone amounts disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119456,"accession_number":"0001356576-25-000068","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Supernus Q3 rev $192M, up 9%; growth products up 52%; ONAPGO supply constraint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $192.1M (+9% YoY); combined growth product sales $149.2M (+52%).","Qelbree net sales $81.4M (+31% YoY); GOCOVRI $40.8M (+15% YoY).","ONAPGO net sales $6.8M in first full quarter; supply constraint pauses new patient starts.","ZURZUVAE collab revenue $20.2M (post Sage acquisition); Q3 U.S. sales up ~150% YoY.","Full-year 2025 revenue guidance raised; cash $281.2M at Sep 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":507380000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119455,"accession_number":"0001356576-25-000065","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus schedules Q3 2025 earnings release for Nov 4 after market close","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Financial results to be released after market close on Tuesday, November 4, 2025.","Conference call at 4:30 p.m. ET with CEO Jack Khattar and CFO Tim Dec.","Live webcast available on Supernus investor relations website; replay for 60 days.","No preliminary financial data provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119454,"accession_number":"0001356576-25-000062","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K/A","filed_at":"2025-10-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Supernus closes Sage acquisition for $8.50/share + CVRs; pro forma shows $118M H1 loss","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed July 31, 2025; Supernus paid $8.50 per share cash plus CVRs up to $3.50 per share.","Pro forma net loss of $118.2M for six months ended June 30, 2025; $415.9M loss for FY 2024.","Contingent consideration liability of $35.7M recorded for CVRs tied to ZURZUVAE sales milestones.","Sage's marketed drug ZURZUVAE (postpartum depression) added to Supernus portfolio; collaboration with Biogen.","Supernus funded acquisition with cash and marketable securities; equity awards settled in cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136019,"accession_number":"0001356576-25-000053","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus Q2 2025: Qelbree +31%, Sage acquisition closed, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues Q2 2025: $165.5M vs $168.3M; non-GAAP rev ex-Trokendi/Oxtellar up 17% YoY.","Qelbree net sales $77.6M (+31% YoY); GOCOVRI net sales $36.7M (+16% YoY); 225k IQVIA prescriptions.","Adjusted operating earnings (non-GAAP) $40.9M; operating income $12.1M; raising FY 2025 guidance.","Closed Sage Therapeutics acquisition on July 31, adding ZURZUVAE; ONAPGO launch: 750+ enrollment forms."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":315277000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136018,"accession_number":"0001356576-25-000050","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Supernus appoints Frank Mottola as Chief Technical Operations Officer, effective June 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frank Mottola promoted from SVP, Quality, GMP Operations and IT to Chief Technical Operations Officer.","Annual base salary increased from $392,500 to $412,500.","2025 bonus target raised from 35% to 40% of base salary.","All other compensatory terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136017,"accession_number":"0001104659-25-072506","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Supernus closes Sage acquisition for $8.50/share + up to $3.50 CVR; ~$561M cash, accretive in 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total cash consideration ~$561M; 36.3M shares (58%) tendered; merger closed July 31, Sage wholly owned.","CVR milestones: $0.50 for Japan approval of ZURZUVAE by June 2026; $1.00 each for U.S. sales thresholds $250M–$375M.","Acquisition adds ZURZUVAE (postpartum depression) and CNS discovery platform; expected cost synergies up to $200M annually.","Acquisition expected to be accretive to Supernus earnings in 2026; stock delisting of SAGE from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136016,"accession_number":"0001356576-25-000046","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus announces Q2 2025 earnings release and conference call on Aug 5, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Press release states Q2 2025 results will be reported after market close on August 5, 2025.","Conference call with President/CEO Jack Khattar and CFO Tim Dec on August 5 at 4:30 p.m. ET.","No preliminary financial results or guidance are provided in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153055,"accession_number":"0001356576-25-000042","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Supernus stockholders elect directors, approve say-on-pay and KPMG ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carolee Barlow and Jack Khattar re-elected as Class I directors; ~46.1M and ~46.5M votes for, respectively.","Non-binding advisory vote on executive compensation approved: ~45.8M for, ~1.7M against.","Ratification of KPMG as independent auditor for FY2025 passed: ~49.2M for, ~0.3M against.","Record date April 22, 2025; 55,989,623 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153054,"accession_number":"0001104659-25-059687","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Supernus acquires Sage Therapeutics for up to $795M ($12/share including CVR)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Supernus to acquire Sage via tender offer at $8.50/share cash plus CVR up to $3.50/share, total up to $795M.","CVR milestones tied to Zurzuvae net sales thresholds ($250M–$375M in U.S. by 2027–2030) and Japan approval.","Deal expected to close Q3 2025; funded from Supernus's cash; cost synergies up to $200M annually.","ZURZUVAE (zuranolone) for postpartum depression is the key asset; Supernus records 50% of U.S. net revenue via Biogen collab.","Transaction unanimously approved by both boards; expected to be significantly accretive in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153053,"accession_number":"0001356576-25-000038","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus receives Paragraph IV ANDA filings for Qelbree; patents expire 2029-2035","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Received Paragraph IV notice letters for ANDA of viloxazine ER capsules 100, 150, 200 mg.","Six Orange Book patents listed; three expire Sept 2029, two Feb 2033, one April 2035.","Company intends to vigorously enforce its Qelbree intellectual property rights.","Currently reviewing details of the ANDA filings from third parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153052,"accession_number":"0001356576-25-000031","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus Q1 2025: Qelbree sales +44% to $64.7M; ONAPGO launched; total revenue +4% to $149.8M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["First quarter 2025 total revenue $149.8M, up 4% YoY; operating loss $(10.3)M vs $(3.2)M in prior year.","Qelbree net sales $64.7M (+44% YoY); GOCOVRI net sales $30.7M (+16% YoY).","ONAPGO (apomorphine infusion) launched in U.S. in April 2025 for Parkinson's motor fluctuations.","Adjusted operating earnings (non-GAAP) increased 16% to $25.9M; full year 2025 guidance reaffirmed.","Qelbree prescriptions grew 22%; March 2025 monthly Rx hit all-time high of 75,277."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":149824000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153051,"accession_number":"0001356576-25-000020","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus to announce Q1 2025 results and host call on May 6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2025 financial results to be reported after market close on Tuesday, May 6, 2025.","Conference call and webcast at 4:30 p.m. ET on May 6, hosted by CEO Jack Khattar and CFO Tim Dec.","Participants may pre-register for dial-in; replay will be available for 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171837,"accession_number":"0001356576-25-000015","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus FY 2024 rev $661.8M; Qelbree +72%; ONAPGO approved; SPN-820 Phase 2b fails","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $661.8M (+9% YoY); Qelbree net sales $241.3M (+72%) and GOCOVRI $130.8M (+9%).","Full year 2024 operating earnings $81.7M vs loss of $(5.3)M in 2023; adjusted operating earnings $183.7M (+47%).","ONAPGO (apomorphine) FDA approved for advanced Parkinson's; launch planned in Q2 2025.","SPN-820 Phase 2b in treatment-resistant depression failed primary and secondary endpoints; program future under review.","FY 2025 guidance: total revenues $600-630M; adjusted operating earnings $105-130M, down from $183.7M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":661817000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171836,"accession_number":"0001356576-25-000011","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Supernus approves executive salary increases and equity awards for 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jack Khattar base salary raised to $1,036,000; 2024 bonus $826,254; awarded 331,660 options and 198,996 PSUs.","CFO Timothy Dec base salary raised to $504,900; 2024 bonus $229,160; awarded 40,000 options, 4,500 RSUs, 5,000 PSUs.","Three other execs (Bhatt, Rubin, Mottola) got salary increases, 2024 bonuses, and similar equity grants.","All 2025 bonus targets unchanged from 2024; salary increases effective Jan 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171835,"accession_number":"0001356576-25-000008","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus SPN-820 Phase 2b misses primary endpoint in treatment-resistant depression","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPN-820 showed MADRS score change of -12.3 vs placebo -11.9 at Week 4; p=not significant.","No statistically significant improvement on any secondary endpoints versus placebo.","Safety profile consistent with prior trials; few adverse events and well-tolerated.","CEO Jack Khattar expressed disappointment; will review data with partner Navitor Pharmaceuticals.","Study enrolled ~250 adults with TRD across 40 U.S. clinical sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171834,"accession_number":"0001356576-25-000006","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus schedules Q4 and full year 2024 earnings release and call for Feb 25, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Earnings release expected after market close on Tuesday, February 25, 2025.","Conference call at 4:30 pm ET hosted by CEO Jack Khattar and CFO Tim Dec.","Live webcast accessible on Supernus Investor Relations website; replay for 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171833,"accession_number":"0001356576-25-000004","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus receives FDA approval for ONAPGO as first subcutaneous apomorphine infusion device for Parkinson's","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ONAPGO approved for continuous treatment of motor fluctuations in advanced Parkinson's patients not controlled by oral levodopa.","Phase 3 study: ONAPGO reduced daily OFF time by 2.6 hours vs 0.9 hours placebo (p=0.0114); GOOD ON time increased 2.8 vs 1.1 hours.","Product will be available in the U.S. in Q2 2025, with a support team including nurse education programs.","Most common adverse events (≥10%): infusion-site nodule, nausea, somnolence, infusion-site erythema, dyskinesia, headache, insomnia.","CEO Jack Khattar stated ONAPGO demonstrates Supernus' continued commitment to CNS innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171832,"accession_number":"0001356576-25-000002","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus announces FDA label update for Qelbree with new pharmacodynamic and lactation data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved updated Qelbree label including serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition data.","New lactation data show transfer of viloxazine into breastmilk is low; relative infant dose ~1% of maternal dose.","Qelbree is first ADHD treatment to receive labeling approval under 2019 FDA guidance on Clinical Lactation Studies.","Label update applies to Qelbree (viloxazine extended-release capsules) for ADHD in patients 6 years and older.","Company cites commitment to building evidence for Qelbree use in ADHD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188839,"accession_number":"0001356576-24-000069","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.05","9.01"],"status":"ready","headline":"Supernus updates Code of Ethics and Business Conduct on Dec 19, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board of Directors approved an updated Code of Ethics and Business Conduct on December 19, 2024.","Updates clarify reporting channels, consequences for violations, conflicts of interest, and compliance guidance.","No waivers or implicit waivers were granted; code will be posted on the Investor Relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188838,"accession_number":"0001356576-24-000065","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus Q3 revenue $175.7M (+14% YoY); raises FY guidance; Qelbree sales +68%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of Qelbree $62.4M (+68% YoY); GOCOVRI $35.6M (+8% YoY) in Q3 2024.","Total revenue $175.7M (+14% YoY); operating earnings $40.9M; adjusted operating earnings $67.7M.","Raising full year 2024 guidance for total revenues and operating earnings (GAAP and Non-GAAP).","SPN-820 Phase 2a in MDD: rapid decrease in depressive symptoms, 80% decrease in suicidal ideation; Phase 2b data H1 2025.","SPN-817 Phase 2a in treatment-resistant seizures: 56% median seizure reduction; Phase 2b expected start by end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":487658000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188837,"accession_number":"0001356576-24-000062","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Supernus SPN-820 Phase 2a shows rapid antidepressant response: 50% MADRS rate at 4 hours","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPN-820 achieved 50.0% MADRS response rate and 35.0% remission rate at 4 hours post-dose in open-label Phase 2a study.","By Day 10, response rate improved to 84.2% and remission to 63.2% in adults with major depressive disorder.","Company notes positive early data; continues development and discussions with potential partners for Sunseeker asset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188836,"accession_number":"0001356576-24-000060","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus sets Q3 2024 earnings call for November 4 after market close","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Earnings release scheduled for Monday, November 4, 2024, after market close.","President/CEO Jack Khattar and CFO Tim Dec to host conference call at 4:30 p.m. ET.","Webcast replay available for 60 days on investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188835,"accession_number":"0001356576-24-000058","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Supernus SPN-820 Phase 2a data: rapid depressive symptom reduction with favorable tolerability","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HAM-D6 score improved -6.1 at 2 hours, -9.6 at Day 10; MADRS improved -16.6 at 4 hours, -22.9 at Day 10.","Suicidal ideation decreased 80% (from 12.5% to 2.6%) over 10 days.","SPN-820 well-tolerated; discontinuation rate 2.5% due to AEs; common AEs: headache, nausea, somnolence, dizziness.","Study enrolled 40 subjects; 38 completed 10-day treatment; open-label, adjunctive to baseline antidepressant.","Phase 2b double-blind placebo-controlled study topline results expected first-half 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188834,"accession_number":"0001356576-24-000056","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus to review Phase 2a data for SPN-820 in major depressive disorder on Oct 17","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company will host webcast and conference call on October 17, 2024 at 4:30 PM ET.","Event will review data from open-label Phase 2a study of SPN-820 for major depressive disorder.","No specific results are disclosed in this filing; data will be presented during the webcast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205316,"accession_number":"0001356576-24-000053","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus announces FDA accepted resubmission of SPN-830 NDA; PDUFA date Feb 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged resubmission of NDA for SPN-830 (apomorphine infusion device) for continuous treatment of motor fluctuations in Parkinson's disease.","Resubmission is considered filed; user fee goal date (PDUFA) set for February 1, 2025.","SPN-830 targets OFF episodes in Parkinson's disease; Supernus focuses on CNS therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205315,"accession_number":"0001356576-24-000049","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus Q2 revenues up 24% to $168.3M; Qelbree sales surge 92%; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 revenues $168.3M (+24% YoY); Qelbree net sales $59.4M (+92% YoY); GOCOVRI $31.7M (+10% YoY)","Operating income $22.6M; adjusted operating earnings $45.5M, up from $10.0M in Q2 2023","Raising full-year 2024 guidance for total revenues and operating earnings (GAAP and non-GAAP)","Resubmitted NDA for apomorphine infusion device (SPN-830) for Parkinson's motor fluctuations","Phase 2b trial of SPN-820 for TRD expected topline data H1 2025; Phase 2 open-label MDD data by end 2024"],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":311969000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205314,"accession_number":"0001356576-24-000041","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus resubmits NDA for SPN-830 apomorphine infusion for Parkinson's OFF episodes","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmitted NDA for SPN-830 (apomorphine infusion device) to FDA for continuous treatment of OFF episodes in Parkinson's disease.","CRL in April 2024 identified two areas needing additional info; no clinical safety or efficacy issues were raised.","Company believes it has fully addressed the FDA's questions from the CRL.","If approved, SPN-830 could be an important novel therapy for Parkinson's patients.","Supernus will continue to work closely with the FDA during the NDA review process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205313,"accession_number":"0001356576-24-000039","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus announces Q2 2024 earnings date: Aug 6 after market close","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2024 financial and business results to be reported after market close on Tuesday, August 6, 2024.","CEO Jack Khattar and CFO Tim Dec will host a conference call at 4:30 p.m. ET on August 6.","Live webcast available on Supernus investor relations website; replay accessible for 60 days.","No preliminary financial results or guidance were provided in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222205,"accession_number":"0001104659-24-072272","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Supernus annual meeting results: directors elected, equity plan increase approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Georges Gemayel and Bethany Sensenig elected with ~48.4M and ~48.6M votes for, respectively.","Say-on-pay proposal approved with 48.2M for, 2.3M against, 1.9M broker non-votes.","Ratification of KPMG as auditor passed with 52.2M for, 272.9K against; no broker non-votes.","Amendment to 2021 Equity Incentive Plan to increase shares passed with 45.5M for, 5.0M against, 1.9M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222204,"accession_number":"0001356576-24-000034","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Supernus reports positive interim Phase 2a data for SPN-817 in treatment-resistant seizures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["75% median focal seizure reduction at 3-4 mg BID in maintenance period; 86% reduction in open-label extension.","81% of focal-seizure subjects had ≥30% reduction; 63% had ≥50% reduction in maintenance period.","Discontinuation rate due to AEs was 22% in titration and 2.4% in maintenance; common AEs: nausea, diarrhea, headache.","Company plans to initiate Phase 2b study before year-end 2024; full Phase 2a topline results expected H2 2024.","CEO states interim data provide strong evidence of clinical utility and potential differentiated treatment option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222203,"accession_number":"0001356576-24-000031","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus to present interim Phase IIa data for SPN-817 on May 23","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim data from open-label Phase IIa study of SPN-817 for treatment-resistant seizures to be reviewed at webcast on May 23, 2024.","Webcast at 4:30 p.m. ET; replay and slides available for 60 days via company website.","No actual clinical results disclosed in this filing; full data release scheduled for the event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222202,"accession_number":"0001356576-24-000026","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus Q1: Qelbree sales +75% to $45.1M; SPN-830 gets FDA CRL; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $143.6M; Qelbree net sales surged 75% YoY to $45.1M (IQVIA Rx +31%).","Operating loss of $(3.2)M; adjusted operating earnings (non-GAAP) of $22.3M.","Full-year 2024 guidance reaffirmed: total revenue $580M-$620M, adjusted op. earnings $80M-$110M.","FDA issued Complete Response Letter for SPN-830 (apomorphine infusion) in Parkinson's; resubmission after May 2024 FDA meeting.","SPN-820 Phase IIb >50% enrolled; topline data H1 2025. SPN-817 interim data call May 23; SPN-443 Phase I planned."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":143644000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222201,"accession_number":"0001356576-24-000022","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Supernus to report Q1 2024 results after market close on May 8, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2024 financial and business results will be released after market close on Wednesday, May 8, 2024.","Conference call and webcast scheduled for 4:30 p.m. ET on May 8, 2024, hosted by CEO Jack Khattar and CFO Tim Dec.","No preliminary financial data or guidance was provided in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222200,"accession_number":"0001356576-24-000020","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John M. Siebert to retire from Supernus Board at June 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John M. Siebert, Ph.D., will retire from the Board effective at the Annual Meeting in June 2024.","Siebert will not stand for re-election; decision not due to any disagreement with the company.","Siebert served on the Board for over a decade."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222199,"accession_number":"0001356576-24-000018","cik":1356576,"company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Supernus receives FDA Complete Response Letter for SPN-830 (apomorphine infusion device)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued CRL stating NDA for SPN-830 (apomorphine infusion) not ready for approval.","Two areas: product quality (additional data submitted but not reviewed) and device master file from manufacturer.","No clinical safety or efficacy issues identified as barriers to approval.","FDA completed successful preapproval inspection of device manufacturer's facility in Feb 2024.","Supernus plans to work with device manufacturer and FDA to resubmit NDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2749051417.2155876,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}